Latest news for Mallinckrodt (OTC:MCKPF) Stock

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which include niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Biotech

Large Cap

News

Health Care

General

HKMPF

HKMPY

MCKPF

MNKTQ

TEVA

VTRS

Increase in production of Takeda&#39;s ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Shortage Relief: More Takeda&#39;s Vyvanse For ADHD On the Way As US Ramps Up Production

MALLINCKRODT PB LTD CO by Mallinckrodt plc.

Mallinckrodt PLC

<a href="https://www.marijuanamoment.net/dea-says-it-didnt-conspire-with-anti-marijuana-group-dismissing-allegedly-illegal-talks-as-gossip/">https://www.marijuanamoment.net/dea-says-it-didnt-conspire-with-anti-marijuana-group-dismissing-allegedly-illegal-talks-as-gossip/</a>
The Drug Enforcement Administration (DEA) and the prohibitionist group Smart Approaches to Marijuana (SAM) have categorically denied allegations that they illegally conspired together during the Biden administration's marijuana rescheduling process.
In a response to a motion seeking to remove DEA from the rescheduling proceedings over alleged ex parte communications with SAM, the agency on Monday said it "unequivocally denies" the charge and requested a dismissal of the motion from Hemp for Victory and Village Farms International.
"Movants' own evidence fails to demonstrate that any unlawful ex parte communication took place," DEA said in its brief with the administrative law judge (ALJ) overseeing the case. "The Movants would have this tribunal embark on a fishing expedition in search of evidence to support these sweeping, unsupported claims, which at best can be categorized as gossip, not ex parte communications."
The original filing included screenshots of social media posts where the group's president, Kevin Sabet, indicated he had private conversations with DEA officials about the rescheduling effort as SAM rallied opposition to the reform and urged the agency to keep marijuana in Schedule I.
One week prior to DOJ's publication of the proposed rule, Sabet posted on X that he could confirm DEA Administrator Anne Milgram wouldn't sign the notice, citing "two confidential sources inside DEA and another outside DEA with intimate knowledge."
The agency said that doesn't amount to ex parte communications, however.
"The tribunal correctly questions the seriousness of the remedies sought by the Movants and as such, should deny the motion," it said in the new filing, referring to comments from the judge last week. DEA added that the cannabis organizations behind the motion failed to "identify any precedent that would support removing an agency from its own rulemaking process."
"The only authority cited by the Movants on this point simply supports the notion that specific individuals may be removed from the proceeding under the appropriate circumstances," it said, pointing out that there is no accusation of any wrongdoing by DEA attorneys involved in the current proceedings on rescheduling. "In short, the Movants' arguments are completely without merit."
SAM also filed a response with the ALJ on Monday, arguing that the allegations "fail on their face to suggest any improper contacts between SAM and the DEA," and therefore they "can and should be quickly dispensed with by this Tribunal."
The organization asserted that, statutorily, unlawful ex parte communications would need to have occurred after the Justice Department posted its notice of proposed rulemaking, which is not explicitly alleged in the original motion.
"Standing alone, that deficiency itself is sufficient to dismiss Movants' speculation about supposed improper contacts," it said.
SAM also cited media reports from outlets including Marijuana Moment and The Wall Street Journal, as well as social media posts from supporters of the rescheduling effort, that contained information about the process that had not yet been made publicly available. It argued that such reporting undermined the allegation that Sabet's communications were uniquely improper.
"In short, the Motion is a transparent effort to smear both SAM and the DEA in an attempt to eliminate from this proceeding one of the strongest voices opposing rescheduling of marijuana," SAM said. "The Tribunal should deny Movants' invitation to create a sideshow requiring SAM and its counsel to expend more time and funds defending against unfounded attacks and instead should permit SAM to focus on the merits of these proceedings."
After the motion was filed with DEA ALJ John Mulrooney, <a href="https://www.marijuanamoment.net/dea-judge-gives-agency-one-week-to-address-allegations-of-illegal-talks-with-marijuana-opponents-amid-rescheduling-process/">the judge invited both the agency</a> <a href="https://www.marijuanamoment.net/dea-judge-invites-prohibitionist-group-to-explain-allegedly-unlawful-talks-with-agency-amid-marijuana-rescheduling-review/">and SAM to respond</a>, calling the nature of the alleged illegal communications "serious."
This comes just weeks before an initial December 2 hearing before the ALJ on the government's proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).
In a historic first, it was Attorney General Merrick Garland—and not DEA's Milgram—who signed the proposed rule to reschedule cannabis. The original motion said that fact, as well as DEA's apparent indecision on the proposed rule, warranted a change in the hearing structure.
The judge, in turn, said that the prospect of removing an agency head from rulemaking that it is responsible for overseeing would likely, "and correctly," be deemed beyond the ALJ office's jurisdiction.
Last week, Mulrooney officially ruled on <a href="https://www.marijuanamoment.net/dea-judge-issues-order-approving-and-denying-witnesses-for-marijuana-rescheduling-hearing-and-laying-out-next-steps/">which of the agency's 25 selected witnesses for the hearing will be able to participate</a>, while laying out the procedure for the administrative process—including how pro- and anti-reform speakers will be able to cross-examine one another.
Separately, the judge last week <a href="https://www.marijuanamoment.net/researcher-asks-dea-judge-to-postpone-marijuana-rescheduling-hearing-until-after-trump-takes-over/">denied a request from a cannabis and psychedelics researcher</a> to postpone the upcoming rescheduling hearing over the agency's alleged "improper blocking" of witnesses, while arguing that the process should be halted at least until President-elect Donald Trump's administration comes into power so it can review the rulemaking.
Mulrooney also <a href="https://www.marijuanamoment.net/dea-judge-rejects-veterans-groups-petition-to-participate-in-marijuana-rescheduling-hearing/">rejected a veterans group's petition to participate in the rescheduling hearing</a>, which the organization called a "travesty of justice" that excludes key voices that would be affected by the potential policy change.
For what it's worth, Vice President Kamala Harris said recently that part of the reason for the delay in the administration's marijuana rescheduling effort is&nbsp;<a href="https://www.marijuanamoment.net/kamala-harris-blames-marijuana-rescheduling-delay-on-dea-bureaucracy-while-defending-her-own-prosecutorial-record/">federal bureaucracy that "slows things down," including at DEA.</a>
In March, Harris also expressed some frustration with the bureaucratic process of rescheduling marijuana, prior to DOJ's formal recommendation,&nbsp;<a href="https://www.marijuanamoment.net/watch-live-vp-harris-talks-marijuana-ahead-of-white-house-meeting-with-cannabis-pardon-recipients/">calling on DEA to expediently finish the job</a>.
While the Biden–Harris administration facilitated the review that led to the DOJ rescheduling proposal, Trump has also voiced support for the reform.
In Congress, numerous lawmakers have shared their own perspectives on the proposed reform with DEA and DOJ since the Schedule III announcement was made.
In August, for example, Sen. Chuck Grassley (R-IA)&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-demands-answers-on-rush-to-reschedule-marijuana-from-top-biden-administration-officials/">raised concerns about the Biden administration's justification</a>&nbsp;for recommending marijuana rescheduling, demanding answers to questions from federal agencies about how they arrived at that decision in what he described as a rushed and unconventional administrative process.
A week earlier, top Democratic senators—including&nbsp; Senate Majority Leader Chuck Schumer (D-NY)—sent a separate letter to DOJ's Garland and DEA's Milgram urging the agencies to&nbsp;<a href="https://www.marijuanamoment.net/schumer-booker-and-other-senators-push-dea-to-promptly-finalize-marijuana-rescheduling/">"promptly finalize" the rule to reschedule marijuana</a>.
While rescheduling would remove certain research barriers and free up state-licensed cannabis business to take federal tax deductions under the Internal Revenue Service (IRS) code known as 280E, it would not federally legalize marijuana, as the&nbsp;<a href="https://www.marijuanamoment.net/marijuana-businesses-could-advertise-in-newspapers-and-magazines-if-rescheduling-is-approved-congressional-researchers-say/">Congressional Research Service (CRS) has made known in multiple recent reports</a>.
Meanwhile, two additional congressional lawmakers have joined the ranks of GOP members who are challenging what they say is&nbsp;<a href="https://www.marijuanamoment.net/gop-lawmakers-demand-answers-from-biden-administration-about-unusual-marijuana-review-process-behind-rescheduling-push/">the "unusual" process that led the Biden administration to propose rescheduling marijuana</a>, expressing concern about how the review was carried out and demanding answers.
Rep. Doug LaMalfa (R-CA)&nbsp;<a href="https://www.marijuanamoment.net/gop-congressman-says-marijuana-rescheduling-and-banking-reform-would-prop-up-an-immoral-industry/">condemned the Biden administration's push to reclassify marijuana</a>, as well as legislative efforts to enact bipartisan cannabis banking reform, because he says the policy changes would "prop up this immoral industry" and give a "green light to the evil that comes from drug use."
Sen. Bill Cassidy (R-LA) also blasted the Biden administration over what he described as&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-condemns-lack-of-transparency-in-marijuana-rescheduling-process/">repeated refusals from federal agencies to brief Congress</a>&nbsp;on its plans and justification for rescheduling marijuana, which he argues fuels speculation that the proposed policy change is politically motivated.
Similarly, 25 GOP congressional lawmakers sent a public comment letter in July opposing the administration's planned rescheduling of marijuana, specifically alleging&nbsp;<a href="https://www.marijuanamoment.net/gop-lawmakers-push-justice-department-to-reverse-course-on-marijuana-rescheduling/">the government's recommendation was based on politics rather than science</a>.

AKAN

CRON

FLGC

GRWG

IMCC

LFLY

MAPS

MSOS

SNDL

TLRY

Tom Angell Says "DEA says it is in the process of preparing public access to the cannabis rescheduling proceedings docket. For now, read Marijuana Moment's coverage of the latest significant filings:", 'DEA And Anti-Marijuana Group Deny Allegations They Conspired During Rescheduling Process' - Marijuana Moment

As the world hurtles toward an electrified future, the copper market <a href="https://www.benzinga.com/topic/copper">stands at a crossroads</a>. 
Insights from JPMorgan analysts Patrick Jones, Greg Shearer and Bill Peterson paint a complex picture: short-term hurdles for copper prices, but a glittering long-term outlook driven by electric vehicles and evolving supply dynamics.
This could seem as good news for those invested in United States Copper Index Fund ETV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPER#NYSE">CPER</a>), Global X Copper Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>), iShares Copper and Metals Mining ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICOP#NASDAQ">ICOP</a>) for the long-term.
<h2 class="wp-block-heading">EV Boom: Supercharging Copper Demand</h2>
The electric vehicle revolution is set to electrify copper demand. JPMorgan predicts copper usage in EVs will more than double from 1.4 million metric tons in 2023 to 3 million by 2030. While some worry that technological advances like thinner copper anode foils could dampen demand, the analysts argue otherwise. 
Larger EV sizes and a pivot toward lithium-iron-phosphate (LFP) batteries — which are more copper-intensive — are expected to drive long-term growth.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41337566/trump-2-0-trade-policies-could-hit-copper-stocks-harder-warns-jpmorgan-analyst">Trump 2.0 Trade Policies Could Hit Copper Stocks Harder, Warns JPMorgan Analyst</a>
<h2 class="wp-block-heading">New Technologies: Leaching A Lifeline?</h2>
Leaching technologies are generating buzz, but can they revolutionize copper supply? Not yet, say the analysts. While projects from major miners like Freeport-McMoRan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) and BHP Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) are on the horizon, these advancements are unlikely to offset supply declines before 2030.
At best, leaching could add 550,000 metric tons annually, just 2% of global supply.
<h2 class="wp-block-heading">Scrap &amp; Recycling: The Unsung Hero?</h2>
Recycling is a crucial cog in the copper machine, accounting for about 17% of refined supply in 2024, up from 14% in 2020. JPMorgan forecasts scrap supply will grow by 5-6% annually, faster than historical rates, yet insufficient to bridge the long-term deficit. Recycling alone won't solve copper's supply crunch.
<h2 class="wp-block-heading">Near-Term Risks, Long-Term Rewards</h2>
JPMorgan warns of near-term risks from macroeconomic pressures, particularly a potential devaluation of the Chinese yuan to 7.8 to 8.0 per U.S. dollar. This could lead to a 12-15% dip in copper prices, presenting headwinds for equities. However, the analysts remain bullish on the long-term trajectory, underpinned by a looming supply-demand gap.
Their picks? 
Lundin Mining Corp (OTCPK: LUNMF) leads in EMEA, while Teck Resources Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) tops the Americas. Asia-Pacific favorites include Zijin Mining and Merdeka Copper, with caution advised on Jiangxi Copper and Sandfire Resources.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41877899/trump-re-election-jolts-metals-market-as-gold-sees-a-stumble-not-a-sea-change">Trump Re-Election Jolts Metals Market As Gold Sees A &#8216;Stumble, Not A Sea Change&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Specialty ETFs

Commodities

Markets

Trading Ideas

ETFs

COPX

CPER

ICOP

LUNMF

TECK

Copper's High-Wire Act: Can EVs, New Tech Power The Metal's Next Big Surge?

Chemed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) short percent of float has risen 6.38% since its last report. The company recently reported that it has 259 thousand shares sold short, which is 2.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Chemed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Chemed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Chemed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Chemed's peer group average for short interest as a percentage of float is 8.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Chemed?

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 8.33% since its last report. The company recently reported that it has 6.62 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.64%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(LLY) - Analyzing Eli Lilly's Short Interest

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 4.50 million shares sold short, which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VRTX

Looking Into Vertex Pharmaceuticals's Recent Short Interest

Rumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares are trading higher Monday after the company announced that streamer Dr. Disrespect will provide exclusive content to Rumble Premium and lead <a href="https://www.benzinga.com/pressreleases/24/11/g42162724/dr-disrespect-will-lead-rumble-gaming-join-rumble-premium">Rumble Gaming as an advisor</a>.
What Happened: Rumble announced Monday morning that Dr. Disrespect will begin streaming his content on the Rumble platform as part of an agreement that includes equity with milestones as a majority of its compensation.
Dr. Disrespect is set to provide exclusive content to Rumble Premium for his &#8220;Champions Club&#8221; community and lead Rumble Gaming, acting as an advisor and helping build the Rumble Gaming community.
Dr. Disrespect will make his Rumble debut on Dec. 2. Rumble will be offering a $10 discount for new subscribers to his community as part of the launch. 
&#8220;Rumble is in a new era, and I&#8217;m laser-focused on expanding into two categories: gaming and crypto. Dr Disrespect will give a much-needed injection into our gaming category,&#8221; said Chris Pavlovski, chairman and CEO of Rumble.
See Also: <a href="https://www.benzinga.com/markets/24/11/42158373/trumps-commerce-secretary-pick-howard-lutnicks-fund-owns-1-19b-in-nvidia-804m-in-tesla-here-is-a-look-at-his-portfolio">Trump&#8217;s Commerce Secretary Pick Howard Lutnick&#8217;s Fund Owns $1.19B In Nvidia, $804M In Tesla: Here Is A Look At His Portfolio</a>
<h3 class="wp-block-heading">How To Buy RUM Stock</h3>
By now you're likely curious about how to participate in the market for Rumble &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. 
In the case of Rumble, which is trading at $7.23 as of publishing time, $100 would buy you 13.83 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RUM Price Action: <a href="http://benzinga.com/quote/rum">Rumble shares</a> were up 13.3% at $7.35 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

Why Rumble Stock Is Rising Monday: 'Laser-Focused' On Gaming, Crypto Expansion

WIIM

FANG

TRGP

Shares of oil and gas companies are trading lower following reports suggesting an Israel-Hezbollah ceasefire.

Macro Economic Events

Economics

Oil is trading lower on reports of an Israel-Hezbollah ceasefire.

Shineco's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NYSE">SISI</a>) short percent of float has fallen 26.15% since its last report. The company recently reported that it has 967 thousand shares sold short, which is 2.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Shineco Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732559420_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Shineco has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Shineco's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Shineco's peer group average for short interest as a percentage of float is 4.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SISI

Looking Into Shineco's Recent Short Interest

Applied Optoelectronics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NYSE">AAOI</a>) short percent of float has fallen 10.57% since its last report. The company recently reported that it has 10.81 million shares sold short, which is 25.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.58 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Applied Optoelectronics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732559415_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Applied Optoelectronics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Applied Optoelectronics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied Optoelectronics's peer group average for short interest as a percentage of float is 5.94%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AAOI

Looking Into Applied Optoelectronics's Recent Short Interest

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has fallen 12.8% since its last report. The company recently reported that it has 61.87 million shares sold short, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732559410_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(PFE) - Analyzing Pfizer's Short Interest

Linda McMahon is no stranger to working with President-elect Donald Trump and will likely be a member of the new White House administration pending an official nomination <a href="https://www.benzinga.com/general/restaurants/24/11/42043491/rfk-jr-wants-donald-trump-to-cut-out-mcdonalds-the-stuff-that-he-eats-is-really-like-bad">and Congressional approval.</a>
Here's a look at McMahon's history with Trump and her investing portfolio linked to her long-running history in the sport of wrestling.
What Happened: Most recently serving as the co-chair of Trump's 2024<a href="https://www.benzinga.com/general/entertainment/24/08/40422152/will-trump-body-slam-2024-election-new-transition-team-co-chair-led-wwe-for-decades"> election transition team</a>, McMahon has been announced as Trump's pick to be the next secretary of the Department of Education.
Trump has previously said he wants to do away with the Department of Education, which could put an emphasis on McMahon to eliminate items from the department and pick which items to save and place under other departments.
While McMahon's lack of experience in the education sector is being scrutinized, it would be hard to say that the Trump pick doesn't have success leading businesses.
McMahon helped grow WWE from 1980 to 2009 and is credited with helping to build the brand through product merchandising and television deals, two key items that turned the wrestling and sports venture into one of the largest worldwide.
WWE is now a unit of TKO Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), a sports holding company that also owns the UFC.
Before a <a href="https://www.benzinga.com/general/entertainment/23/09/34455843/wwe-and-ufc-merge-on-tuesday-heres-what-you-need-to-know">merger with UFC</a> in 2023, WWE had been in the McMahon family for over 70 years.
WWE is not as close to the McMahon family as it once was. Linda's husband and high school sweetheart Vince McMahon stepped away from WWE in 2022 due to an ongoing scandal and later stepped down from a leadership role with TKO Group Holdings in 2024 over sex trafficking lawsuits.
The couple is currently separated, according to <a href="https://www.cnn.com/2024/11/21/business/linda-mcmahon-abuse-wwe-trump-education/index.html">CNN</a>.
The McMahons are worth an estimated $3 billion together with the vast majority of the family wealth related to the past interest in WWE and current stakes in TKO Group Holdings.
A report from <a href="https://wrestlenomics.com/articles/2024/who-owns-wwe-after-the-tko-merger-and-before/">Wrestlenomics </a>said Vince McMahon has sold portions of his TKO Group Holdings stock, but Linda McMahon has not sold her stake.
The Washington Post <a href="https://www.washingtonpost.com/politics/2024/11/19/linda-mcmahon-trump-administration-wwe-allegations/">lists </a>Vince's TKO Group Holdings stake valued at around $950 million and Linda's stake valued at around $67 million.
Linda McMahon currently <a href="https://s3.amazonaws.com/sec.irpass.cc/2660/0001474506-24-000117.pdf">serves </a>as an independent director on the board of directors for Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), the media company co-founded by Trump.
SEC filings reveal that McMahon does not hold shares of the company and was not paid in 2022 or 2023 for her role as a director. McMahon may receive DJT shares as non-cash compensation "from time to time" according a filing.
If approved as the next Department of Education lead, McMahon is expected to place her financial holdings in a blind trust and resign from board memberships according to her counsel Laura Brevetti.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent112524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Close Connections to Trump: After leading WWE for many years, McMahon stepped down in 2009 to pursue politics. McMahon ran for a U.S. Senate seat two times, losing in the 2010 and 2012 general elections after securing the Republican Party nomination.
McMahon has been a donor to the Republican Party and past Trump campaigns, which is part of the family's friendship with the president-elect. Trump and Vince's friendship dates back to 1988 when the duo worked together on a Wrestlemania near a Trump-owned casino and a storyline involving the millionaires.
Linda McMahon previously served as the head of the Small Business Administration (SBA) from 2017 to 2019 under Trump, making her one of the few returning faces to the next White House administration under Trump.
McMahon previously stepped down from the SBA to take on a new role as part of his 2020 re-election campaign team. The former wrestling leader has also helped lead a political action committee (PAC) connected to Trump.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/politics/24/11/42077496/donald-trumps-personnel-picks-new-poll-finds-elon-musk-with-highest-approval-by-voters-matt-gaetz-with-highest-disapproval">Donald Trump&#8217;s Personnel Picks: New Poll Finds Elon Musk With Highest Approval By Voters, Matt Gaetz With Highest Disapproval</a></li>
</ul>
Photo: Gage Skidmore<a href="https://www.flickr.com/photos/gageskidmore/26657337398/in/photolist-GBBPFu-2ixQ4FX-24FB123-GBCowj-GBCg29-23ofSyR-21ZoNYQ-rX5kE1-2m5GkMn-24FAAvA-rVkEPz-rXdCLR-rXdAZ4-rX5u2G-2m5Gm3s-2m5AWAD-seBNkR-scnQVq-2m5BXkQ-scnKpW-24KnBFH-23EAETQ-eFrvnc-eFs31k-22oAMgk-eFrWS2-eFyaUJ-eFrz7r-HhygqH-eFrU8F-eFrJH8-eFruSt-eFruhv-2nGksFC-eFrV7p-eFxGHG-QF9wD8-eFs2cn-eFrjac-eFrgtc-eFrVZT-eFxLnb-eFxZhW-mEWF7B-eFrwuH-eFxNY9-eFrdgr-eFrGZr-eFxSuw-ncWSte"> via </a>Flickr Creative Commons

Entertainment

Government

Education

Politics

Sports

Trump's Department Of Education Secretary Pick Linda McMahon Owns TKO Stock Thanks To Famous Wrestling Past

Market Summary

Benzinga Market Summary: S&P Gains, 10-Year Falls, Target Stock Rises, Oil Falls On Reports Of Israel-Hezbollah Ceasefire

<a href="https://www.racefans.net/2024/11/25/cadillac-has-agreement-in-principal-to-enter-f1-in-2026-ben-sulayem/">https://www.racefans.net/2024/11/25/cadillac-has-agreement-in-principal-to-enter-f1-in-2026-ben-sulayem/</a>
&nbsp;
FIA president Mohammed Ben Sulayem has confirmed Formula 1 is working towards adding an 11th team to the grid for the 2026 season.
Ben Sulayem said the General Motors brand has an "agreement in principle" to join the series.
&nbsp;
The FIA approved an application to enter the world championship from Andretti Global in October last year. However Formula One Management must also give its approval for any new team to join the grid, and it rejected the application earlier this year.
However rumours during the Las Vegas Grand Prix weekend claimed FOM was preparing to announce a reversal of its position which would allow the new entrant to arrive in 2026.
Andretti obtained the backing of General Motors brand Cadillac, which announced it planned to enter as as the team's power unit supplier in 2028. Since then Michael Andretti has stepped down in charge of the Silverstone-based project, prompting speculation Cadillac would rebrand the entire entry.
Ben Sulayem, who <a href="https://www.racefans.net/2023/10/08/fia-president-ben-sulayem-confident-andretti-cadillac-will-join-f1-grid/">said last year he was "confident" the team would join the series</a>, has given the clearest indication yet FOM is seriously considering a U-turn on its opposition to the project.

FWONA

FWONK

'Cadillac Has "Agreement In Principle" To Enter F1 In 2026 – Ben Sulayem' - RaceFans

The special counsel filed a motion to dismiss Donald Trump's election-obstruction case without prejudice, which means the case could be revived in the future.
 <a href="https://www.washingtonpost.com/national-security/2024/11/25/trump-cases-motion-to-dismiss-jack-smith/" title="https://www.washingtonpost.com/national-security/2024/11/25/trump-cases-motion-to-dismiss-jack-smith/">https://www.washingtonpost.com/national-security/2024/11/25/trump-cases-motion-to-dismiss-jack-smith/</a>

'Special counsel Jack Smith moves to dismiss Trump's D.C. prosecution' - Washington Post

Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its transformative impact on the software sector.
The analyst projects a monumental shift driven by generative AI adoption, enterprise consumption, and large language model (LLM) launches. As a result, Ives has upgraded Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) and Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) to Outperform and raised price targets for Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) and Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) to reflect their enhanced growth potential.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch" rel="noreferrer noopener">Amazon Strengthens Anthropic Partnership with $8 Billion AI Investment</a>
Ives notes Snowflake has moved past its &#8220;optimization&#8221; phase, citing substantial quarter-over-quarter improvements in product revenue. Snowflake stands to gain from the explosion of AI use cases over the next 12 to 18 months, positioning itself as a pivotal player in the enterprise adoption of generative AI.
The analyst upgraded Snowflake to Outperform, raising its <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings" target="_blank" rel="noreferrer noopener">price target to $190</a>, supported by a 30x long-term free cash flow (FCF) estimate.
For Elastic, Ives highlights its strategic alignment with enterprises shifting to next-generation platforms. Customers are consolidating spending by moving from legacy vendors to Elastic&#8217;s AI-powered solutions bolstered by the company&#8217;s express migration program.
Ives upgraded Elastic to Outperform with a new <a target="_blank" href="https://www.benzinga.com/quote/ESTC/analyst-ratings" rel="noreferrer noopener">price target of $135</a>, based on 8x its fiscal year 2026 enterprise value-to-revenue (EV/Revs) ratio.
Ives raised his <a target="_blank" href="https://www.benzinga.com/quote/PLTR/analyst-ratings" rel="noreferrer noopener">price target for</a> Palantir from $57 to $75, leveraging a 38x long-term FCF target. He cites Palantir&#8217;s groundbreaking AIP strategy, which enables enterprises to harness AI across diverse use cases. The company&#8217;s robust product suite is expected to drive unprecedented demand as businesses increasingly recognize its value.
Ives increased his <a target="_blank" href="https://www.benzinga.com/quote/CRM/analyst-ratings" rel="noreferrer noopener">price target for</a> Salesforce from $325 to $375, citing a 28x long-term EBITDA valuation. His research indicates rising customer enthusiasm for Salesforce&#8217;s AI-integrated product offerings, which drive the company&#8217;s next wave of growth.
Ives sees the broader software sector as entering an inflection point, projecting $2 trillion in AI spending in the coming years. With enterprises set to adopt AI at scale by 2025, companies like Snowflake, Elastic, Palantir, and Salesforce are poised to benefit from this unprecedented technological revolution.
Price Actions: SNOW stock is up 3.12% at $172.67 at last check Monday. ESTC is up 3.85%, PLTR is up 0.80% and CRM is down 0.21%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42140725/snap-denies-facilitating-child-exploitation-seeks-dismissal-of-state-lawsuit" target="_blank" rel="noreferrer noopener">Snap Denies Child Exploitation Allegations, Wants Lawsuit Dismissed</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Equities

Upgrades

Price Target

Reiteration

Analyst Ratings

ESTC

PLTR

SNOW

Snowflake, Elastic Poised For AI Revolution Gains, Analyst Upgrades The Stocks

Pump.fun, <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38897152/solana-meme-coin-platform-pump-fun-exploited-for-1-9m-vows-to-repay-users">a decentralized platform</a> for creating Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based meme coins, has come under intense scrutiny after reports of harmful and violent behavior surfaced on its livestream feature.
What Happened: The platform, which has gained popularity in the crypto space, is now facing backlash from the community, with many calling for the livestream function to be disabled altogether until proper moderation tools are in place.
Concerns about the platform escalated on Nov. 25 when a user livestreamed a disturbing incident.
Beau, a Pudgy Penguins safety project manager, <a href="https://x.com/beausecurity/status/1860859118124138610">reported</a> on X (formerly Twitter) that an individual on Pump.fun threatened suicide if their coin failed to reach a specific market capitalization.
Beau urged the platform to intervene immediately, disable the livestream and offer support to the individual.
Other alarming incidents include a user allegedly firing a gun out of a window each time their meme coin&#8217;s value increased, and a child threatening harm to family members if a token price goal wasn't met. 
One of the most distressing reports involved a user claiming they would carry out a school shooting if their coin didn't pump. 
Community members labeled the livestream feature a "pipeline of felonies," with many urging Pump.fun to shut it down until better safeguards are introduced.
The platform's livestream feature has become a flashpoint for criticism. 
One X user commented, "Turning on a camera to showcase your own depravity to the world isn't noble or novel," emphasizing the need for immediate deactivation of the feature.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42169183/dont-get-fooled-by-the-success-of-dogecoin-shiba-inu-76-of-x-twitter-influencers-promote-dead-meme-coins-study-reveals">Don&#8217;t Get Fooled By The Success Of Dogecoin, Shiba Inu: 76% Of X (Twitter) Influencers Promote Dead Meme Coins, Study Reveals</a>
Why It Matters: The concerns are reflected in Polymarket predictions, where users are actively betting on whether Pump.fun will disable its livestream feature by Friday.
The prediction market <a href="https://polymarket.com/event/pumpfun-ends-livestreaming-by-friday?tid=1732551799626">indicates</a> only a 21% chance the livestream will be shut down by Friday, highlighting skepticism about the platform's ability to act swiftly in addressing these issues.
Alon, the pseudonymous leader of Pump.fun, <a href="https://x.com/a1lon9/status/1860036153249787911">defended</a> the platform's moderation efforts while acknowledging the community's concerns.
"We have a large team of moderators working around the clock and an internal team of engineers dealing with increased scale," Alon said. 
He stressed that moderation has been a priority since the platform's inception and assured users that harmful content is being addressed.
Despite these assurances, critics argue that Pump.fun's measures are insufficient given the severity of the incidents. 
The community continues to demand more transparency and immediate action to prevent harmful broadcasts. 
However, the platform has not disclosed specific plans for additional safeguards or changes to its livestream feature.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42166673/drug-cartels-use-tether-and-bitcoin-to-launder-millions-court-documents-reveal">Drug Cartels Use Tether And Bitcoin To Launder Millions, Court Documents Reveal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

Solana Meme Coin Platform Pump.Fun Faces Backlash Over Scandalous Livestreams, But Polymarket Traders Aren't Convinced It'll Go Dark

TSLA

New California EV Credit Would Exclude Tesla Under Proposal

TECH

Bio-Techne shares are trading higher after Gemini Bioproducts acquired the company's product rights and inventory of selected fetal bovine serum.

Deep-pocketed investors have adopted a bullish approach towards Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WDAY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Workday. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 63% leaning bullish and 27% bearish. Among these notable options, 3 are puts, totaling $139,697, and 8 are calls, amounting to $359,531.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $260.0 to $305.0 for Workday over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Workday stands at 409.9, with a total volume reaching 1,857.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Workday, situated within the strike price corridor from $260.0 to $305.0, throughout the last 30 days.
<h3>Workday Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732558526_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$7.3</td>
<td>$6.7</td>
<td>$7.33</td>
<td>$287.50</td>
<td>$71.1K</td>
<td>15</td>
<td>210</td>
</tr>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$13.8</td>
<td>$13.7</td>
<td>$13.7</td>
<td>$275.00</td>
<td>$68.5K</td>
<td>84</td>
<td>65</td>
</tr>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$6.6</td>
<td>$6.2</td>
<td>$6.55</td>
<td>$290.00</td>
<td>$65.5K</td>
<td>159</td>
<td>1.0K</td>
</tr>
<tr>
<td>WDAY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.4</td>
<td>$260.00</td>
<td>$59.6K</td>
<td>1.9K</td>
<td>192</td>
</tr>
<tr>
<td>WDAY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$40.8</td>
<td>$39.6</td>
<td>$40.15</td>
<td>$280.00</td>
<td>$40.1K</td>
<td>134</td>
<td>10</td>
</tr>
</tbody>
</table>

<h3>About Workday</h3>
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 18,000 employees.
Having examined the options trading patterns of Workday, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Workday Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,595,656, the WDAY's price is up by 0.26%, now at $268.44. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>Expert Opinions on Workday</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $303.3333333333333.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Loop Capital persists with their Hold rating on Workday, maintaining a target price of $270. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $300. 
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Outperform, setting a price target of $340. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Workday, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

WDAY

Check Out What Whales Are Doing With WDAY

Mallinckrodt reports Q4 results

Small Cap

Press Releases

Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

Earnings

Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance

Mallinckrodt

In a significant move to mitigate the ongoing shortage of ADHD medications in the U.S., the Drug Enforcement Administration (DEA) has authorized a substantial increase in the production limits for Takeda Pharmaceutical Co Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/23/06/32948636/adhd-medication-shortage-worsens-vyvanse-supply-dwindles-amid-adderall-scarcity" rel="noreferrer noopener">Vyvanse and its generic versions</a>.



Following the FDA&#8217;s request in July, the production of Vyvanse, known chemically as lisdexamfetamine, will increase by 24%. This decision addresses not only the domestic shortfall but also the rising international demand.



The shortage of ADHD drugs, notably Vyvanse and Adderall, a product of Israel-based Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), has been exacerbated by manufacturing delays and a spike in demand.



Recognized by the DEA as a Schedule II controlled substance, lisdexamfetamine requires additional prescribing safeguards due to its high potential for abuse.



The DEA&#8217;s recent production adjustment includes an additional 6,236 kilograms of lisdexamfetamine, divided into 1,558 kilograms to meet the increased U.S. demand and 4,678 kilograms for international markets.



&#8220;These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally,&#8221; <a target="_blank" href="https://public-inspection.federalregister.gov/2024-20114.pdf" rel="noreferrer noopener">stated</a> the DEA.



Further bolstering the supply chain, Reuters highlighted the FDA last year approved generic versions of Vyvanse from 11 drug manufacturers, including U.S.-based Mallinckrodt Plc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MCKPF#OTC">MCKPF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MNKTQ#OTC">MNKTQ</a>) and Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), UK-based Hikma Pharmaceuticals Plc, (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HKMPF#OTC">HKMPF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HKMPY#OTC">HKMPY</a>) and Indian drugmaker Sun Pharmaceutical Industries.



These approvals came after Takeda&#8217;s exclusivity on the drug ended, opening the market to more players and <a href="https://www.benzinga.com/general/biotech/22/10/29248173/fda-signals-shortage-for-teva-pharmas-adhd-drug-due-to-manufacturing-delay" target="_blank" rel="noreferrer noopener">potentially stabilizing supply</a>.



Price Action: TAK shares are down by 0.10% to $14.91 at the last check on Friday.



Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40738760/dollar-stores-struggle-when-walmart-performs-well-report" target="_blank" rel="noreferrer noopener">Dollar Stores Struggle When Walmart Performs Well: Report</a>.</li>
</ul>

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production

Comments

Mallinckrodt

News

Latest news for Mallinckrodt (OTC:MCKPF) Stock

Friday, September 06, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga